Top 5 Papers
#1
Source: New England Journal of Medicine | Authors: Yothers G et al. (Alliance A021502)
Score: 10/10 — NEJM Phase III; practice-changing new adjuvant standard for dMMR stage III colon cancer
The phase 3 ATOMIC trial randomized 712 patients with resected stage III dMMR colon cancer to adjuvant atezolizumab plus mFOLFOX6 (6 months chemo + 12 months total atezolizumab) versus mFOLFOX6 alone. At median follow-up of 40.9 months, 3-year disease-free survival was 86.3% vs 76.2% (HR 0.50; 95% CI 0.35-0.73; P<0.001). Five-year overall survival was 89.7% vs 87.9% (HR 0.90). Grade 3-4 adverse events were higher with atezolizumab, mainly fatigue. This establishes atezolizumab + mFOLFOX6 as the new adjuvant standard of care for dMMR stage III colon cancer.
Post angle: Practice-changing for #ColonCancer: ATOMIC trial in NEJM shows adding atezolizumab to adjuvant chemo cuts recurrence risk by 50% in dMMR stage III patients. New standard of care. #CRCResearch #GIOncology
#2
Source: New England Journal of Medicine | Authors: Tabernero J et al.
Score: 9.5/10 — NEJM Phase III; doubles OS in BRAF V600E mCRC (30.3 vs 15.1 months); FDA approved
The phase 3 BREAKWATER trial evaluated first-line encorafenib + cetuximab + mFOLFOX6 versus standard chemotherapy (+/- bevacizumab) in BRAF V600E-mutant metastatic CRC. PFS was significantly improved (12.8 vs 7.1 months; HR 0.53; P<0.001). In an interim analysis, median OS was 30.3 vs 15.1 months (HR 0.49; P<0.001), representing an unprecedented survival gain in this aggressive CRC subtype. The triplet regimen received FDA approval and represents the new standard of care for first-line BRAF V600E mCRC.
Post angle: Landmark NEJM data: BREAKWATER doubles survival in BRAF V600E #mCRC with encorafenib/cetuximab/mFOLFOX6. OS 30 vs 15 months. From worst to manageable prognosis. #CRC #PrecisionOncology
#3
Source: New England Journal of Medicine | Authors: Park W et al. (Memorial Sloan Kettering)
Score: 9/10 — NEJM Phase I; first-in-class KRAS G12D degrader; breakthrough for pancreatic cancer
This phase 1 study reports the first clinical results of setidegrasib (ASP3082), a first-in-class KRAS G12D-targeted protein degrader that forms a ternary complex with KRAS G12D and VHL E3 ligase. In patients with KRAS G12D-mutant pancreatic cancer, approximately 25% achieved objective responses with median OS of 10 months. Two-thirds of patients had progressed on 2+ prior lines. This represents a major breakthrough in targeting KRAS G12D, which drives ~40% of pancreatic adenocarcinomas and was previously considered undruggable.
Post angle: The 'undruggable' is now druggable: setidegrasib degrades KRAS G12D protein in #PancreaticCancer (NEJM). 25% response rate in heavily pretreated patients. A new era for KRAS-targeted therapy. #PancCancer #KRASG12D
#4
Source: ASCO GI 2026 / Journal of Clinical Oncology | Authors: Lenz HJ et al. (NRG-GI004/SWOG-S1610)
Score: 8.5/10 — Phase III at ASCO GI; practice-changing for metastatic dMMR CRC
The phase 3 COMMIT trial compared FOLFOX + bevacizumab + atezolizumab versus atezolizumab monotherapy in first-line dMMR/MSI-H metastatic CRC. The triplet achieved significantly longer PFS (>2 years vs ~5 months; HR 0.44; P=0.01) and higher ORR (86.1% vs 46%, with complete responses in 36.1% vs 18.9%). Grade 3-4 AEs were higher with the triplet (73.2% vs 41.5%). No OS difference was noted at analysis. These results challenge the IO-monotherapy paradigm in dMMR mCRC.
Post angle: COMMIT challenges IO monotherapy in dMMR #mCRC: adding chemo+bev to atezolizumab boosts ORR to 86% and PFS to >2 years. Is the triplet the new 1L standard? #ASCOGI2026 #CRC
#5
Source: ASCO GI 2026 / Lancet Gastroenterology & Hepatology | Authors: Shitara K et al.
Score: 8/10 — Phase III; potential new standard HER2-targeting agent for 1L HER2+ GEA
The phase 3 HERIZON-GEA-01 trial evaluated zanidatamab, a bispecific HER2-targeted antibody, combined with chemotherapy as first-line treatment in HER2-positive locally advanced/unresectable or metastatic gastroesophageal adenocarcinoma. Results presented at ASCO GI 2026 demonstrated that zanidatamab plus chemo can slow cancer growth and extend survival compared to standard trastuzumab-based therapy. Zanidatamab may become the new standard-of-care HER2-targeting agent in this setting.
Post angle: Could zanidatamab replace trastuzumab in HER2+ #GastricCancer? HERIZON-GEA-01 phase III results are compelling. A new bispecific era for GEA. #ASCOGI2026 #HER2 #UpperGI
Additional Papers of Interest
-
FDA / OncLive — ORR 46.5%, mPFS 11.3 months in FGFR2-altered CCA; PDUFA date September 27, 2026.
-
ASCO GI 2026 (Abstract 13) — ORR 64.4% vs 39.2%; supports encorafenib/cetuximab across chemo partners.
-
Phase 2 (ONO-4578-08) — EP4 antagonist added to nivo/chemo improved PFS in HER2-neg gastric cancer.
-
ASCO GI 2026 — ORR 37%, DCR 78% at 1,200 mg; encouraging activity in KRASG12D PDAC.
-
Nature Reviews GI & Hepatology — International expert consensus on latest CCA developments and research priorities.
Back to all digests